论文部分内容阅读
目的:研究卡托普利(Cap)对血管的结构与功能的作用是否与其降压作用分离。方法:SHR从胎仔期起分别接受Cap 20与100mg·kg~(-1)·d~(-1),A组和B组)至生后16周停药,40周实验。血压用尾动脉法测定。肠系膜动脉第三级分支的壁/腔比测定用形态计量法,阻力血管性质测定用后肢灌注压对递增量phenylephrine,灌注液内加L-NAME或L-arginine。结果:两种剂量的Cap都能完全 防止血管壁肥厚(肠系膜动脉第三级分支的壁/腔比Cap A:0.38±0.08,Cap B:0.29±0.05 vsWKY:0.34±0.11,P>0.05)结果与WKY者类似。Cap组后肢灌注压曲线的参数与WKY组几乎完全相同,与未治疗SHR有明显差别(EC_(50),Cap B:4.05±2.58 vs SHR:1.15±0.96 mL·L~(-1),P<0.01,vs WKY:5.13±1.97mL·L~(-1),P>0.05)。在灌注液内加入L-NAME或L-arginine可加强或减弱Cap治疗组的血管收缩反应。结论:Cap从胎仔期治疗可以使SHR的阻力血管结构与收缩反应正常化,而血压仍维持在不同程度的较高水平。
AIM: To investigate whether the effect of cap on the structure and function of blood vessels is separated from its hypotensive effect. Methods: SHR was administered Cap 20 and 100 mg · kg -1 · d -1, group A and group B respectively from the first trimester to the first 16 weeks after birth, and the experiment was stopped at 40 weeks. Blood pressure was measured by tail artery. The mesenteric artery third branch of the wall / cavity ratio determination by morphometry, resistance vascular properties measured with hind limb perfusion pressure increasing amount of phenylephrine, perfusate plus L-NAME or L-arginine. Results: Both doses of Cap completely prevented vascular wall hypertrophy (wall / lumen ratio of CapA: 0.38 ± 0.08, Cap B: 0.29 ± 0.05 vsWKY: 0.34 ± 0.11, P> 0.05) in the third grade branch of mesenteric artery Similar to WKY. The parameter of hindlimb perfusion pressure curve in Cap group was almost the same as that of WKY group, and there was a significant difference (P <0.05) between SHR and control group (Caps: 4.05 ± 2.58 vs 1.15 ± 0.96 mL·L -1, P <0.01, vs WKY: 5.13 ± 1.97mL·L -1, P> 0.05). The addition of L-NAME or L-arginine to the perfusate enhances or attenuates vasoconstrictive responses in Cap-treated groups. CONCLUSIONS: Cap treatment from fetal stage normalizes resistance vascular structures and contractile responses in SHR, while blood pressure remains elevated to varying degrees.